AbbVie (ABBV) Gains FDA Nod for At-Home Skyrizi Induction in Crohn's Disease

gurufocus.com · 2026-10-23

On October 23, 2026, AbbVie Inc (NYSE: ABBV) announced FDA approval for a new subcutaneous induction regimen for its drug Skyrizi, enabling adults with moderate

TickrTrends take: AbbVie received FDA approval to administer Skyrizi induction therapy at home for Crohn's disease patients, potentially expanding the drug's addressable market and reducing treatment barriers. This approval could drive revenue growth for the company's immunology franchise, though TickrTrends currently identifies ABBV as overvalued within the Healthcare sector. Investors focused on valuation metrics should monitor whether this label expansion translates into earnings growth sufficient to justify current pricing in coming quarters.

Read the full story at gurufocus.com →